MAY 30, 2018 06:00 AM PDT

Phenotypic Profiling for Improving Drug Discovery Productivity

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Chief Scientific Officer, Translational Biology, Eurofins DiscoverX
    Biography
      Dr. Ellen L. Berg is Chief Scientific Officer for the DiscoverX BioSeek Business Unit. Dr. Berg is responsible for the BioMAP® platform of human primary cell-based assays and predictive analysis tools. Dr. Berg was a founder and the CSO of BioSeek, acquired by DiscoverX in 2012, and previously led a research team at Protein Design Labs developing novel therapeutic antibodies for inflammatory diseases. She is an expert in in vitro models of human disease and tissue biology, holds a number of patents, and has authored over 75 publications in the areas of inflammation, systems biology, phenotypic drug discovery, and drug and toxicity mechanisms of action. Dr. Berg has served in various positions with the Society of Laboratory Automation and Screening and is a member of the Society of Toxicology.

      Dr. Berg has a Ph.D. from Northwestern University and was a Postdoctoral Fellow at Stanford University.

    Abstract:

    The pharmaceutical industry’s productivity crisis is well known with >90% of drug candidates failing in clinical testing, primarily due to unexpected toxicity or lack of efficacy.  Despite advances in high throughput ‘omics technologies and the large volume of information that is now amassed on new drug candidates, the probability of success for new molecules is not improving.  Scannel and Bosney (2016) have pointed to a lack of predictive preclinical models as one of the key factors.  New approaches using human-based in vitro cell systems are showing promise for replacing the use of animal models, particularly in cases where animal testing has failed to predict human effects. These new approaches will be described along with case studies that illustrate how these methods can generate mechanistic hypotheses for drug induced cardiovascular toxicity.  Also to be discussed is how phenotypic assay data may be incorporated into safety risk assessments through the adverse outcome pathway framework being developed for chemical safety testing.


    Learning Objectives: 

    1. Learn about non-animal based in vitro assays for preclinical testing in drug discovery.
    2. Review some of the factors that make it challenging to predict drug efficacy in clinical testing.
    3. Find out about new hypotheses underlying cardiovascular disease and drug induced cardiotoxicity.


    Show Resources
    You May Also Like
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources